Phase II Study of Postoperative Intensity-modulated Radiotherapy (IMRT) Combined With Capecitabine for Stage II/III Gastric Cancer Patients
In Intergroup 0116, only 64% patients in concurrent chemoradiation group completed treatment
as planed, but in recently reported ARTIST trial, capecitabine was admitted to concurrent
with radiotherapy,patients who completed treatment as planed in concurrent group reach high
as 80%. IMRT is an advanced radiotherapy technology which allows high conformal dose
distribution to Planing Tumor Volume (PTV) and low dose to organ at risk. The purpose of
this study is to evaluate feasibility and efficacy of concurrent IMRT combined with
capecitabine for the treatment of gastric cancer patients after D1/2 surgery.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
feasibility of concurrent IMRT combined with capecitabine for the treatment of gastric cancer patients
feasibility of concurrent IMRT combined with capecitabine is defined as toxicities (CTC-AE 3.0) and rate of patients complete concurrent chemoradiation according to protocol.
3 months after concurrent chemoradiation
jing jin, professor
Cancer Hospital, Chinese Academy of Medical Science
China: Food and Drug Administration